Humedics — which specializes in real-time and mobile measurement of the individual liver function at the bedside of the patient — has closed a Series C round totaling more than 6.3 million Euro.
Two new international investors, Vesalius Biocapital Partners and Seventure Partners, led the round with participation of all VC investors from previous rounds. As part of the deal, Vesalius’ Managing Partner Dr. Christian Schneider and Dr. Robert Schier from Seventure Partners will join Humedics board of directors.
The existing syndicate includes Peppermint Venture Partners (managing the Charité Biomedical Fund), VC Fonds Technologie managed by IBB-Beteiligungsgesellschaft, ERP Startfonds of the Kreditanstalt für Wiederaufbau (KfW), Ventegis and High-Tech Gründerfonds.
The new funds will be used for the European market entry of Humedics’ proprietary LiMAx test and the corresponding FLIP diagnostic device.
Humedics makes a breath-based diagnostic system, enabling clinicians to quantitatively determine the individual liver function capacity for a patient within minutes. It allows for better risk assessment in liver surgery and thus, “superior surgery planning” as well as selecting treatment strategies optimally adapted to the individual patients liver status. The LiMAx test is touted to provide certainty for the physician, safety for the patient and leads to cost reduction for the hospital.